我从公司网页上摘录了一些内容，不过我对临床试验阶段不了解，也不知道他们做到了什么程度，希望有人说说
http://www.phosphagenics.com/main/pharms_TPM02.htmTPM-02
The TPM-02 delivery system has been shown to be suitable for delivering both relatively small molecules as well as macromolecules up to 30,000 Daltons in size. Examples of the later successfully delivered to date include insulin (lispro and the hexamer) and fragments of the hormone PTH (1-34).
TPM-02 is a multi-lamellar malleable vesicular carrier whose size can be tightly controlled. This allows TPM-02 to be formulated in a range of sizes, from nanometres to microns in diameter.
With respect to transdermal delivery, due to the physio/chemical characteristics (i.e. the softness and malleability of the TPM-02 outer layer), these vesicles are able to pass through the tight junctions between skin cells and as such do not get deposited in the upper layers of the skin, such as the stratum corneum or the epidermis.
Additionally, as this technology allows for the size of the vesicles to be controlled, the rate of diffusion through the skin (and as a result the systemic release rate) can also be controlled.
http://www.phosphagenics.com/main/Release_22-05-2007.htmPhase 1b insulin clinical trial commenced
Melbourne, Australia, 22 May 2007: Phosphagenics Limited (ASX: POH) (AIM: PSG) (ADR/OTC: PPGNY) announced today that it has commenced the Phase 1b clinical trial of its transdermal insulin product, TPM-02/Insulin.